tiprankstipranks
Trending News
More News >

Shanghai Fosun Pharma Strengthens Governance with New Nomination Committee

Story Highlights
Shanghai Fosun Pharma Strengthens Governance with New Nomination Committee

Don’t Miss TipRanks’ Half-Year Sale

An update from Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) is now available.

Shanghai Fosun Pharmaceutical has established a Nomination Committee under its board of directors to enhance its corporate governance structure. This committee is tasked with selecting and recommending candidates for the company’s directors and senior management, thereby ensuring a robust leadership framework that aligns with the company’s strategic goals.

The most recent analyst rating on (HK:2196) stock is a Hold with a HK$17.20 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.

More about Shanghai Fosun Pharmaceutical (Group) Co

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a joint stock limited company based in China, operating within the pharmaceutical industry. The company focuses on the development, manufacture, and distribution of pharmaceutical products and medical devices, with a strong emphasis on innovation and corporate governance.

Average Trading Volume: 7,025,116

Technical Sentiment Signal: Buy

Current Market Cap: HK$65.06B

See more data about 2196 stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1